Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...
Jordi Remon, Paolo Bironzo, Nicolas Girard et al.· Mediastinum· 0 citations
Little is known about the natural history of epidermal growth factor receptor (
EGFR)
-mutated non-small-cell lung cancer (NSCLC) in Caucasian patients treated with surgery before the generalization of adjuvant treatment with osimertinib.
The primary objective of this study was to describe the outcomes...
J. Auliac, P. Thomas, O. Bylicki et al.· Therapeutic Advances in Medi...· 0 citations
BACKGROUND
Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...
R. Descourt, A. Mogenet, Maelys Consigny et al.· Annals of Oncology· 0 citations
INTRODUCTION
Identification of populations eligible for lung cancer screening (LCS) is a priority question in this field. The primary objective of this study was to quantify lung cancer prevalence after a first round of LCS among patients with history of atheromatous cardiovascular disease (aCVD) and tobacco exposure....
E. Armand, C. Buton, C. Caramella et al.· Respiratory medical research· 0 citations
BACKGROUND
For advanced lung cancer patients, an increasing number of long responders to Immune Checkpoint Inhibitors (ICI) is observed. Thus, the optimal treatment duration remains unclear whereas indefinite treatment is associated to immune-related adverse events (irAEs) and financial burden.
OBJECTIVE
To describe...
Arnaud De Gunten, A. Mogenet, A. Bronstein et al.· Lung Cancer· 0 citations
Simple Summary In patients with advanced lung cancer harboring targetable gene mutations, sequential immunotherapy-targeted therapy was associated with higher rate of adverse events. A short delay between last immunotherapy administration and targeted therapy administration may increase the risk of serious adverse even...
Thomas Pierret, J. Auliac, C. Ricordel et al.· Current Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.